PubMed Health⌕ Search

Biomedical subjects

O Masamune

Publications and source records attributed to O Masamune.

At least 127 records · Page 7Linked to original sources
PubMed1990

Detection and isolation of a 30 kDa abnormal protein in avian dystrophic muscle.

We have studied the protein composition of the pectoralis superficialis muscle of genetically dystrophic (New Hampshire line 413) and normal control (line 412) chickens by one- and two-dimensional gel electrophoresis. A protein, referred to hereafter as the 30 kDa abnormal protein, was specifically detected in the affected muscle. It was purified to homogeneity, and its molecular properties were studied. It is a monomer with a molecular mass of approximately 30 kDa and an isoelectric point of about pI 8.4. We have screened by Western blotting a variety of muscles from line 412 and line 413 chickens for the presence of the 30 kDa protein. While the pattern of total protein is very similar in all cases, the 30 kDa protein was not detected in the pectoralis superficialis muscle of line 412 chickens. However, the immunoreactive bands were detected in the sartorius muscle and the tensor fasciae latae muscle from dystrophic and normal chickens. Interestingly, the immunoreactive bands of normal skeletal muscles are smaller in molecular weight than those of dystrophic skeletal muscles. To determine the early time sequence of the appearance of the abnormal protein, we studied muscles from embryos and post-hatched chickens at various ages. The abnormal protein was detected in dystrophic muscles as early as 15 days ex ovo and occurred throughout development up to six months ex ovo. Although the implication of the dystrophy-associated appearance of the 30 kDa protein in the affected muscle is not clear at present, it would be of particular interest to elucidate the biochemical functions of the 30 kDa protein in the affected muscle (pectoralis superficialis muscle) of genetically dystrophic chicken.

Animals↗
PubMed1990

HLA antigens on colorectal adenoma and cancer cells.

HLA-DR and -ABC antigens on adenoma and cancer cells of the colon and rectum were investigated. Fifteen specimens of adenomas from 15 patients with sporadic colorectal adenoma, seven specimens of adenomas from seven patients with familial polyposis coli (FPC), and 10 specimens of cancers from 10 patients with colorectal cancer were obtained. Normal colonic mucosa far from the lesions, taken from 15 patients with sporadic adenoma or cancer, served as normal control mucosa. HLA antigens were identified using an immunoperoxidase staining method. Epithelia of all normal control mucosa (n = 15) expressed HLA-ABC antigens, but not HLA-DR antigens. HLA-DR antigens were expressed on 47% (7/15) of sporadic adenomas, 71% (5/7) of adenomas in FPC, and 100% (10/10) of cancers. The extent of HLA-DR expression on adenoma and cancer cells became broader with more severe dysplasia in adenoma, and increased undifferentiation in cancer. It also became broader with increasing mononuclear cell infiltration in both adenomas and cancers. HLA-DR antigens on adenoma and cancer cells appeared to be related to the neoplastic transformation of the epithelia, and to the mononuclear cell infiltration. Partial disappearance of HLA-ABC antigens on adenoma and cancer cells was observed in a few specimens of both adenomas and cancers.

Adenoma↗
PubMed1990

[A new autoantibody, anti-210kDa microtubule associated protein antibody, detected in the serum of patients with various liver diseases and SLE].

A new autoantibody to 210kDa microtubule associated protein (MAP) obtained from rabbit liver excrude was detected in the serum with various liver diseases and SLE. As there were no reports concerning autoantibodies to MAPs in animals and human, it may say that anti-210kDa MAP autoantibody we detected was a new cytoskeleton antibody. Using western blotting method, the anti-210kDa MAP autoantibody was frequently found in the patients with alcoholic liver diseases (52.5%), PBC (55.6%), autoimmune hepatitis (83.3%), SLE (71.4%) but rarely in the patients with viral liver diseases (26.4%) and none in normal controls at a serum dilution of 1:10. In addition, at a serum dilution of 1:100, the anti-210kDa MAP autoantibody was found in the patients with alcoholic liver diseases (22.5%), PBC (44.4%), autoimmune hepatitis (66.7%), SLE (71.4%), viral liver diseases (17.0%) and none in normal controls. It was confirmed that the anti-210kDa MAP autoantibody was frequently detected in cases of alcoholic liver diseases, PBC, autoimmune hepatitis and SLE than in those of viral liver diseases and normal control.

Autoantibodies↗
PubMed1989

Colonic lymphoid cell subsets and epithelial HLA-DR antigens in familial polyposis coli.

Although there has been some evidence suggesting that immunological mechanisms are involved in the pathophysiology of familial polyposis coli (FPC), there has not been any report as to whether there is any abnormality of lymphoid cell subsets as background, whether polyps (adenomas) show different lymphoid cell subsets from the normal mucosa, or whether HLA-DR antigens are expressed on the epithelia of adenomas. Lymphoid cell subsets (CD5, CD4, CD8, IgA1, IgA2, IgM, IgD, IgG, and IgE positive cells) in the lamina propria, and HLA-DR antigens on the epithelia were studied in 7 patients with FPC. From each patient, 2 specimens were obtained from both the normal (non-polypoid) area and the polyp. Normal colonic mucosa, taken from 15 patients with conventional polyps or colorectal cancer, served as the normal control mucosa. Lymphoid cell subsets and HLA-DR antigens were identified by indirect immunoperoxidase staining using mouse anti-human monoclonal antibodies. In the normal area of FPC, lymphoid cell subsets were similar to those of normal control mucosa except for an increase in IgD positive (IgD+) cells. However, definite alterations were observed in the polyp. There were significant increases in the number of CD4+ and IgG+ cells, and in the sum of five classes of Ig+ cells compared to the normal area or normal control mucosa. HLA-DR antigens were not expressed in the normal control mucosa or in the normal areas, and only on the epithelia of the polyp in 5 out of 7 specimens (71%). These results clearly demonstrate that immunological reactions are involved in FPC polyps.

Adenomatous Polyposis Coli↗
PubMed1989

HLA-DR antigen expression in macroscopically uninvolved areas of intestinal epithelia in Crohn's disease.

HLA-DR antigens in small and large intestinal epithelia were examined in Crohn's disease (CD). Seventy-two biopsy specimens (10 from the duodenum, 18 from the terminal ileum, and 44 from various sites of the large intestine) were obtained from 5 patients with CD chronologically; before treatment, during elemental diet (ED) treatment, and during home elemental enteral hyperalimentation (HEEH). HLA-DR antigens on the intestinal epithelia were identified by the indirect immunoperoxidase staining method using two mouse anti-HLA-DR monoclonal antibodies. In the small intestine, HLA-DR antigens were expressed differently from normal controls in macroscopically or microscopically pathological areas, but not in macro- or microscopically normal areas. In the large intestine, when the disease was in full vigor before treatment, HLA-DR antigens were always aberrantly expressed even in the macroscopically uninvolved areas, as well as in macroscopically involved areas. However, when the disease was suppressed after ED followed by HEEH treatment, the antigens were not always expressed in the macroscopically uninvolved areas, or in the macroscopically involved areas. These findings suggest that HLA-DR antigens are not merely expressed as a non-specific response to inflammation, but may be expressed as a primary change which results in macroscopic lesions. The possible role of HLA-DR antigens in the immunological mechanism in CD is proposed.

Adult↗
PubMed1989

Phosphorylation of neurofilament proteins and localization of axonal swellings in motor neuron disease.

Seven lumbosacral spinal cords with motor neuron disease were examined immunocytochemically with monoclonal antibodies (MAb) directed against neurofilament proteins (NFP). Each of the 5 MAbs used in this study was monospecific to one of the triplet of NFP. Two of them were specific to the highly phosphorylated form of high molecular weight peptide of NFP (NFP-H). All 5 MAbs stained all axonal swellings examined. In 2 spinal cords examined, some axonal swellings were found in the anterolateral funiculus and some of these were as far as 1000 microns from the grey matter. This localization of axonal swellings suggests that a high degree of phosphorylation of NFP is not the cause of accumulation of NFP in axonal swellings in motor neuron disease.

Adult↗
PubMed1989

[Efficacy of UFT in advanced gastric carcinoma under comparative study of MMC + UFT and MMC + tegafur therapies].

Antitumor effect of MMC + UFT(A) and MMC + tegafur(B) therapies for advanced gastric carcinoma was compared from February 1985 to March 1988. UFT and tegafur were orally given at dose of 400 mg/m2 daily, and MMC was intravenously administered at dose of 6-8 mg/m2 every two weeks. The following results were obtained. 1. Twenty-nine cases entered in this study were divided into A or B therapies at random. All cases entered were eligible. Fourteen of 29 cases were randomized into A therapy and 15 cases into B therapy. One case treated with B was evaluated as incomplete. 2. There were no differences in the characteristics of patients between A and B therapies. 3. Among 29 eligible cases, a partial response was obtained in 3 out of 14 cases (21.4%) treated with A and in 3 out of 15 cases (20.0%) treated with B. Among 28 cases evaluated completely, a partial response was obtained in 3 out of 14 cases (21.4%) treated with each A and B. 4. Response rate with every ps or for every lesion did not differ between A and B therapies. 5. Median survival day treated with A and B therapies was 223 and 181 days, respectively. The survival curve did not differ significantly between the two therapies. 6. The frequency of adverse reactions within eight weeks after beginning the therapy was 64.2 and 73.3% with A and B therapies, respectively. From the results mentioned, it was concluded that the antitumor effect of UFT was not superior to that of tegafur for advanced gastric carcinoma.

Adult↗